{'fraction_non_alphanumeric': 0.018796992481203006, 'fraction_numerical': 0.006265664160401002, 'mean_word_length': 5.495934959349594, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Measurement of the soluble angiopoietin receptor tie‐2 in patients with coronary artery disease: development and application of an immunoassay

Background The angiopoietin family has emerged as a group of crucial growth factors to normal angiogenesis. They are essential to the development of the mature vessel wall and interact with the endothelium via endothelial cell‐specific tyrosine kinase receptors, tie‐1 and tie‐2. The role of the tie‐2 receptor has been extensively examined in neovascularization associated with malignancy, but little is known about the role it may play in atherosclerosis, a condition whose pathophysiology also involves angiogenesis. Soluble tie‐2 has been detected in the plasma of healthy controls, but this has yet to be applied to patients in the clinical setting.